SIGHT Stock Overview
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
GenSight Biologics S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.40 |
52 Week High | €2.53 |
52 Week Low | €0.30 |
Beta | 2.14 |
1 Month Change | 0% |
3 Month Change | -12.57% |
1 Year Change | -81.04% |
3 Year Change | -94.31% |
5 Year Change | -79.40% |
Change since IPO | -95.09% |
Recent News & Updates
Recent updates
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?
Sep 20Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?
Aug 17Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt
Aug 04GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 14GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
May 10Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long
Feb 02A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary
Dec 09Shareholder Returns
SIGHT | FR Biotechs | FR Market | |
---|---|---|---|
7D | -14.1% | -0.2% | -0.4% |
1Y | -81.0% | -1.8% | 10.6% |
Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -2.2% over the past year.
Return vs Market: SIGHT underperformed the French Market which returned 10.1% over the past year.
Price Volatility
SIGHT volatility | |
---|---|
SIGHT Average Weekly Movement | 11.2% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: SIGHT has not had significant price volatility in the past 3 months.
Volatility Over Time: SIGHT's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 23 | Laurence Rodriguez | https://www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
SIGHT fundamental statistics | |
---|---|
Market cap | €31.24m |
Earnings (TTM) | -€28.87m |
Revenue (TTM) | €3.33m |
9.4x
P/S Ratio-1.1x
P/E RatioIs SIGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SIGHT income statement (TTM) | |
---|---|
Revenue | €3.33m |
Cost of Revenue | €0 |
Gross Profit | €3.33m |
Other Expenses | €32.20m |
Earnings | -€28.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.37 |
Gross Margin | 100.00% |
Net Profit Margin | -867.06% |
Debt/Equity Ratio | -74.6% |
How did SIGHT perform over the long term?
See historical performance and comparison